Edouard Cukierman, Chairman – Cukierman & Co. Investment House
Mr. Edouard Cukierman is the Founder and Managing Partner of Catalyst Investments and serves as the Chairman of Cukierman & Co. Investment House. Since its establishment in 1993, Cukierman & Co. Investment House has been engaged in more than € 5.5 billion cross-border transactions across industries. Catalyst was the only Israeli venture fund that invested in Mobileye.
Prior to establishing and managing Catalyst Investments in 2000, Mr. Cukierman was the President and CEO of Astra Technological Investments, a Venture Capital Fund established in 1993, which was the first Israeli company to go public in Continental Europe.
Today, Edouard Cukierman serves as board member of Tufin technologies, the leading private Cyber security company in Israel, and Dori Media Group in Israel. Edouard Cukierman is the Founder of the GoforIsrael annual conference.
Mr. Cukierman is a board member of "Alliance Israelite Universelle en Israel" and a board member of Sar-El (Association that brings volunteers from across the world to the IDF in Israel). He is also a director of the Asia M&A Association in China.
Edouard Cukierman together with Dr. Daniel Rouach co-authored the book “Israel Valley Le bouclier technologique de l’innovation” published in June 2013 by Edition Pearson in Paris, translated into Chinese in November 2014, and in Italian in June 2016
Mr. Cukierman served for many years as a reserve officer in the Crisis & Hostage Negotiation team and in the Spokesperson’s Unit of the IDF.
Mr. Cukierman holds an MBA from INSEAD, France and a B.Sc. from the Technion – Israel’s Institute of Technology.
Dr. Laurent Choppe, Managing Partner – Cukierman & Co. Life Sciences
Laurent Choppe has lead Cukierman & Co. Life Sciences since 2008 and has been involved in more than 60 medtech and biotech corporate finance transactions and advisory assignments for the Cukierman group. His team works worldwide with venture- backed and middle market companies for fundraising, licensing deals and M&A transactions, as well as strategic projects for key life sciences industry players.
Dr. Choppe is a board member of Israel Brain Technology (IBT) - a non-profit organization whose mission is to accelerate the commercialization of Israel’s brain-related innovation and establish Israel as a leading international brain technology hub.
After a veterinary practice and a new venture management experience, he worked 10 years in Schering-Plough (today Merck & Co.) in marketing positions in dermatology, allergy, respiratory and animal health in France, served as General Manager in Israel and Vice President of Virology, Oncology and Cardiology in Canada. He then served 4 years as International General Manager at Bellus Health (ex-Neurochem, NASDAQ & TSE, dedicated to Alzheimer’s disease and AA amyloidosis).
Dr. Choppe is a Doctor of Veterinary Medicine of the University Paris XII, laureate of the École Nationale Vétérinaire d'Alfort, CES of Veterinary Ophthalmology and earned a MBA from INSEAD (Fontainebleau, France). He is married, father of 3 and lives in Lausanne (Switzerland).
Daniel Cohen, Partner – Cukierman & Co. Life Sciences
Involved with Cukierman Life Sciences since 2008, Daniel has 18 years of experience in Healthcare sector in various positions (Investment Banking, Venture Capital, Fund of Funds, Business Development & Consulting).
Daniel is the CEO & Founder of Sollal Partners, a consulting firm offering management & due diligence services to leading funds in Israel, Europe and China and serves on the board of several Life Science companies.
Prior to Sollal, Daniel managed Fosun Pharma's activity in Israel leading major investments and strategic operations (e.g. Kite Pharma, Tyto Care, Pontifax, Tapingo...), served as Principal at Credit Agricole Private Equity Israel and Director at Market Bridges.
Efi Cohen-Arazi, Founder & CEO – Rainbow Medical
Mr. Efi Cohen Arazi, CEO and Co-Founder of Rainbow Medical, Israel’s leading medical device innovation house focused on inventing and developing game changing solutions for sizeable unmet market needs in the area of hypertension, ophthalmology, cardiology and diabetes. Rainbow Medical’s shareholders include Medtronic, Abbott and Sony corporations. Mr. Cohen-Arazi has over 25years of experience in the medtech and biotech industries where he held executive management responsibility in both operations and business management. Prior to establishing Rainbow Medical, Mr. Cohen-Arazi served as Co-Founder & CEO of IntecPharma, Israel, a company specializing in drug development and delivery and as Chairman of CollPlant Ltd., a both public companies traded in Tel-Aviv stock exchange. Previously, Mr. Cohen-Arazi was GM & V.P., Site Head at California based Amgen Corporation, where he established and led several global strategic initiatives and partnerships to develop and manufacture blockbuster biopharmaceuticals. Prior to Amgen, Mr. Cohen-Arazi was Senior VP at Immunex Corporation in Washington and before that VP and General Manager at the Merck-Serono Group in Switzerland and Israel. Mr. Cohen-Arazi holds advanced degrees in Agriculture and Microbiology from the Hebrew University of Jerusalem
Guy Spigelman, VP Portfolio Success - aMoon
Guy Spigelman is VP of Portfolio Successat aMoon, a leading VC in the HealthTech and Bio-Tech space with over $750M under management. Previously, Guy served as CEO of PresenTense – a network of start-up accelerators that launches over 100 startups per year, and one of the leading Social Enterprise support organizations in Israel. In this role, Guy founded 7 new accelerator programs, including A3i – the first accelerator in the world focused on Assistive and Aging Technologies. Prior to PresenTense, Guy served as EVP of Business Development at Apos, an aMoon portfolio company, where he was responsible for the establishment and management of subsidiaries in Europe and APAC. Before this role, Guy held various executive sales, marketing, busines development and product positions at Israeli software companies, including XMPie that was acquired by Xerox and the NASDAQ listed Radview.
Guy serves as a Major (reserves) in the IDF Spokesperson Unit, and was the Chairperson of Merchavim – an NGO promoting shared society at over 500 schools and kindergartens across Israel.Guy lives in Tel Aviv with Naomi and their three daughters, Eden, Galia and Neta.
Dr. Pini Orbach, Head of Pharma – Arkin Holdings
Dr. Pini Orbach joined Arkin Holdings in 2010 as Head of its Pharma Division. Dr. Orbach is a member of the board in several of its pharmaceutical companies, including UroGen Pharma and Quiet Therapeutics, from which he shares his extensive hands-on drug development and business experience. He originally gained his foundation in US based companies such as, Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ, EPIX), as well as Israeli-based companies such as, cCAM BioTherapeutics - a cancer immunotherapy company, which was sold to Merck in 2015 for $605M. He holds a Ph.D. from the Department of Physiology and Functional Genomics, University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center, Harvard Medical School - Massachusetts General Hospital.
Dr. Yuval Cabilly, General Partner - Israel Biotech Fund
Dr. Cabilly is one of the three founders and a Managing Partner of Israel Biotech Fund. He serves on the Board of Directors of TPCera Ltd. and is an Observer of the Board of Directors of Pharma Two B Ltd. Dr. Cabilly is also co-founder and Board Member of 8400 – The Health Network. Prior to the formation of the Fund, Dr. Cabilly managed the investment portfolio of the Cabilly family, which focuses primarily on healthcare start-ups in Israel and elsewhere. Dr. Cabilly was responsible for identifying, funding and engaging in business development activities for its 20+ companies, including seven Israeli Pharma start-ups in pre-clinical, Phase I and Phase II clinical stages. Dr. Cabilly received his Ph.D. in molecular cell biology from Tel Aviv University, where he focused his research on a neurodegenerative disease, and several of his articles have been published in well-known scientific journals. Dr. Cabilly is based in Israel and devotes his full time to managing the Fund.
Ariel Beery, CEO – MobileODT
Ariel Beery is co-founder and Chief Executive Officer of MobileODT, a company transforming healthcare by offering a family of smart, AI-powered internet-connected medical devices that health care providers can use at the point-of-care for a variety of examinations. Our leading product is the Enhanced Visual Assessment (EVA) System for colposcopy, used for women's health services in 26 countries around the world (and 31 States in the US). Prior to MobileODT, Ariel served as the Global CEO of the PresenTense Group, an accelerator for social ventures he co-founded in 2005 that has launched over 1000 startups. Ariel has a B.A in Economics and Political Science from Columbia University, a MPA (Masters in Public Administration) from New York University (NYU) in Management, and an MA from NYU in Jewish Studies.
Jordan Rubinson, CEO - Regenera
Mr. Rubinson has worked for more than 25 years in the pharmaceutical industry with large pharma companies like Pfizer, GlaxoSmithKline, and Aventis.
He is currently the CEO of Regenera Pharma, an Israeli biotech company with a drug targeting diseases of the Central Nervous System. The company’s lead drug candidate is being studied in a phase 3 clinical trial for stroke of the optic nerve and a phase 2 clinical study in Canada for mild/moderate Alzheimers.
Mr. Rubinson worked previously in early stage companies as chief commercial officer for Champions Oncology, where he grew sales 30% annually to $20M and brought the company to profitability. Just prior, Mr. Rubinson was the CEO of Polyheal Ltd, which was sold to TEVA at a $90M valuation.
While in pharma, Mr. Rubinson worked at Pfizer as the marketing director for Israel. At GSK in U.S. marketing, he managed assets of over $300M in annual sales, brought to market several category-leading vaccines, and earned the company’s Frost and Sullivan Market Engineering Excellence Award.
He also worked at GSK France, managing a large field force division of over 100 employees. While at Aventis, Mr. Rubinson had assignments in France, Canada and the U.S. Mr. Rubinson holds an engineering degree from Columbia University and an MBA from MIT’s Sloan School of Management.
Anne Rogov, Senior Associate – Gurnet Point Capital
Annie Rogove is a Senior Associate at Gurnet Point Capital, a healthcare investment fund based in Cambridge, MA that invests across all stages of product development through to commercialization with a hybrid venture and private equity strategy encompassing life sciences and medical technologies. During her time at Gurnet Point, Annie has been an integral member of the investment team, working on public and private transactions worth over $1.5 billion across a wide range of deal structures. Prior to Gurnet Point, Annie spent over four years with L.E.K. Consulting in Boston, Sydney and New York. As a member of the firm’s Life Sciences and Med Tech practice, Annie advised clients ranging from startups to the world’s largest pharmaceutical companies on M&A, portfolio prioritizations, and strategic initiatives.
Dr. Nissim Darvish, Senior Managing Director – Orbimed Advisors Israel
Nissim is a veteran of the lifescience industry, with 15 years of experience covering medical technology development, corporate leadership and investment management. Nissim spent eight years with Pitango, where he was a General Partner managing life sciences investments. Previously, Nissim was the founder and CEO of Impulse Dynamics, which he led for six years, culminating in a $250 million realization event. Nissim obtained his M.D. and Ph.D. in Biophysics and Physiology from the Technion in Israel, and subsequently conducted his postdoctoral research at the NIH. He has published over 100 patents, authored over 20 publications and received eight prizes and awards.
Zeev Zehavi,VP Venture Investments - Johnson & Johnson Development Corporation
Zeev Zehavi is Vice President of Venture Investments for Johnson & Johnson Innovation - JJDC, Inc. (JJDC) and joined in 1999. He is based out of offices in Israel and Belgium. Mr. Zehavi’s background covers an extensive array of health care and related businesses. He spent over 10 years with Teva Pharmaceutical Industries, Ltd., including a five-year assignment as President of the bulk chemical business in North America. He returned to Israel as President of Clal Pharmaceutical Industries (CPI) for four years before starting his own consulting business, Pharma Zee, Ltd. While operating this consultant business for medical device and pharmaceutical start-up companies, Mr. Zehavi initiated contacts with various Johnson & Johnson companies.
Mr. Zehavi holds a Bachelor of Science from Hebrew University of Jerusalem and a Master of Business Administration in Marketing and Finance from Tel Aviv University. He is fluent in Hebrew, English, and Arabic.
Jacob Keidar, Ambassador of the State of Israel to Switzerland and Liechtenstein
Yair Shiran, Minister of Commercial Affairs and Deputy Permanent Representative of Israel to the WTO - Geneva, Switzerland
Yair Shiran joined the Government of Israel in 1992. Since then, he has been serving in senior diplomatic and executive positions in Israel and Abroad,
Mr. Shiran assumed his responsibilities as Minister-Commercial Affairs and Deputy Permanent Representative of Israel to the World Trade Organization, in Geneva/Switzerland in August 2018.
Prior to that, Mr. Shiran served as the Head of the Industry Administration in the Ministry of Economic Affairs. In that position, he was responsible for shaping industrial policy and regulations, aiming to support Industrial development throughout the country, and particularly, in the periphery. In parallel, he served as the Chairman of the TRQ Committee that was charged with the task of introducing reforms in the Israeli food market, so as to enhance competition and reduce the prices of basic food products to the consumers. From 2006 to 2011, Mr. Shiran served as Israel's Economic Minister to North America. Based in New York City, he was responsible for the Government’s effort to promote bilateral trade and to strengthen economic collaboration between Israel and the United States. Between 2002 and 2006, Mr. Shiran served as the Director of International Agreements and Trade Policy at the Ministry of Industry, Trade and Labor. In this position, Mr. Shiran served as the Chief Trade Negotiator for international trade agreements with Israel’s key trading partners, including the U.S., Canada, Egypt, Turkey, as well as other European and Asian countries. During this, term Mr. Shiran headed the Israeli delegation to the trilateral trade negotiations that led to the signing of the historic US-Egypt-Israel QIZ agreement. This agreement resulted in an immediate increase of 250% in the volume of bilateral trade between Israel and Egypt. Between 1996-2001, Mr. Shiran served in the Mission of Israel to the World Trade Organization (WTO) in Geneva. During his first term in Geneva, he was elected to Chair the WTO committees on Information Technology and Market Access.
For the past decade Mr. Shiran has also been lecturing as an Adjunct Professor at a number of Business Schools, including The Hebrew University of Jerusalem, The Arison School of Business at the Interdisciplinary Centre (IDC), Herzliya and at Fox Business School at Temple University in Philadelphia. Mr. Shiran received his Masters of Arts in Public Administration from the Kennedy School of Government at Harvard University, where he studied as a Wexner Fellow. He also holds a Masters of Arts degree in Business Administration and a Bachelors of Arts degree in Economics and Political Science from the Hebrew University of Jerusalem. Mr. Shiran is also a graduate of the Israeli Academy of National Security.